Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Rosuvastatin Lowers Triglycerides in Patients With Modest Cholesterol Levels: Presented at ACC By Ed Susman ATLANTA -- March 19, 2010 -- Treatment of hypertriglyceridaemia with rosuvastatin led patients to achieve at least a 25% reduction in the blood fats, researchers said here at the 59th Annual Scientific Sessions of the American College of Cardiology (ACC). “We believe that this may be the first study of statin therapy among patients with hypertriglyceridaemia that has as its primary endpoint the reduction of triglycerides,” said Juan Talavera, MD, Instituto Mexicano del Seguro Social, Mexico City, Mexico, during his poster presentation on March 14. In the study, 111 patients were treated with rosuvastatin 10 mg and achieved a mean reduction of 26% in triglycerides; the 112 patients who were treated with rosuvastatin 20 mg achieved a mean reduction of 33% in serum triglycerides. Placebo patients reduced triglycerides by 8%. The differences achieved statistical significance (P < .01). “In addition to reducing triglycerides, treatment with rosuvastatin use significantly improved the patients’ overall atherogenic lipid profile,” Dr. Talavera said. He said that guidelines suggest lowering triglycerides in patients with high cholesterol, but the researchers were interested in determining if statin therapy would successfully lower triglycerides even in patients whose cholesterol levels were modestly increased. “These patients may still have an increased risk of cardiovascular disease,” he said. The mean low-density lipoprotein cholesterol (LDL-C) levels among the patients in the study was about 130 mg/dL, and their high-density lipoprotein cholesterol (HDL-C) was about 34 mg/dL. The patients’ LDL-C decreased 35% among those on rosuvastatin 10 mg, by 44% with rosuvastatin 20 mg and increased by 4% among placebo-treated patients (P < .01). Dr. Talavera and colleagues also observed an increase in HDL-C of 12% in the rosuvastatin 20 mg group and 7% in the rosuvastatin 10 mg group, compared with no change among the placebo group (P < .01) The researchers recruited patients who had mean triglyceride levels of about 300 mg/dL. Patients were eligible if they had triglyceride levels between 200 and 800 mg/dL. Their mean age was 53 years and about one-third of the group was women. Dr. Talavera said there were no drug-related adverse events in the study. Funding for this study was provided by AstraZeneca Mexico. [Presentation title: A Double Blind, Randomized, Multicenter, Parallel Group, Placebo Control Trial to Evaluate the Effect of Statin Therapy on Triglycerides Levels in Mexican Hypertriglyceridemic Patients. Abstract 1076-112] E-mail this page to a friend or colleague! To print, use this version